Christopher B. Ehrlich - 08 Oct 2021 Form 4 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (CERO)

Role: CEO and Secretary, Director, 10%+ Owner
Signature: /s/ Chris Ehrlich
Issuer symbol: CERO
Transactions as of: 08 Oct 2021
Net transactions value: +$367,330
Form type: 4
Filing time: 12 Oct 2021, 19:36:09 UTC
Previous filing: 08 Oct 2021
Next filing: 31 Jan 2022
SEC: View on sec.gov

Quoteable Key Fact

"Christopher B. Ehrlich filed Form 4 for PHOENIX BIOTECH ACQUISITION CORP. (CERO) on 12 Oct 2021."

Quick Takeaways

This page summarizes Christopher B. Ehrlich's Form 4 filing for PHOENIX BIOTECH ACQUISITION CORP. (CERO).
3 reported transactions and 2 derivative rows are listed below.
Filing timestamp: 12 Oct 2021, 19:36.

What Changed

Previous filing in this sequence was filed on 08 Oct 2021.
Current net transaction value: +$367,330.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PBAX	Class A common stock	Other	$367,330	+36,733	+5.5%	$10.00	699,996	08 Oct 2021	By Phoenix Biotech Sponsor, LLC	F1, F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PBAX	Class B Common Stock	Other		-82,875	-1.8%		4,596,250	08 Oct 2021	Class A Common Stock	82,875		By Phoenix Biotech Sponsor, LLC	F3, F4, F5
transaction	PBAX	Warrants	Other	$0	+18,366	+5.5%	$0.000000	349,998	08 Oct 2021	Class A Common Stock	18,366	$11.50	By Phoenix Biotech Sponsor, LLC	F1, F5, F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquisition by the issuer's sponsor, Phoenix Biotech Sponsor, LLC (the "Sponsor") in connection with the partial exercise of the underwriters' over-allotment option.
F2	These shares underlie the same number of units of the issuer held by the reporting person.
F3	The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date.
F4	Forfeiture and cancellation of shares of Class B common stock for no consideration because the underwriters' over-allotment option was not exercised in full.
F5	These securities are held directly by the Sponsor, which managed by the reporting person. As a result, all of the securities may be deemed to be beneficially held by the reporting person. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose.
F6	The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering.
F7	The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation.